ABSTRACT
Male breast cancer (MBC) is rare, constituting less than 1% of all diagnosed breast cancer cases, although the incidence of MBC has risen in recent decades. [1] [2] [3] The etiology of MBC is poorly understood. Risk factors include testicular condition, age, obesity, liver disease, benign breast condition, Jewish ancestry, and Klinefelter syndrome, while family history and mutations of BRCA (primarily BRCA2) are the most important factors. [4] [5] [6] [7] [8] Invasive ductal carcinoma is the main histologic type and constitutes approximately 84.8% to 90% of breast cancers in men. 3, 4, 9, 10 MBC shares some features of female breast cancer (FBC), but presents at older age, more often with low to intermediate grades, higher stage, higher rates of hormone receptor positivity, lower rates of human epidermal growth factor receptor 2 (HER2) positivity, more lymph node involvement, increased secondary malignancies, distinct molecular profiles, and overall poorer prognosis. 2, 5, 6, [9] [10] [11] [12] [13] [14] Several molecular tests have been developed (Oncotype Dx, MammaPrint, Prosigna, etc) and utilized clinically in FBC to determine breast cancer patients' recurrence risks. 15 At the same time, many studies have demonstrated that routine histopathologic and immunohistochemical variables can provide prognostic information in FBC. [16] [17] [18] [19] [20] [21] [22] Magee equation(s) is derived by a linear regression analysis using several pathologic variables and semiquantitative immunohistochemical results of estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67 to calculate recurrence score (RS). 16, 17 Previous studies have demonstrated that Magee equation RS effectively predicts prognosis in FBC and correlates well with Oncotype DX (Genomic Health, Redwood City, CA). 16, 17, 23, 24 Due to the relative rarity of MBC, patients' recurrent risks and prognosis of MBC are still not well studied and management is mainly based on experience of FBC. However, no study on use of these tests in MBC patients has been reported. A suitable and effective tool for evaluation of MBC recurrence risk and prognosis is urgently needed. In this study, we aimed to examine the clinicopathologic features of MBC and correlate Magee equation RS with clinical outcome. 
Materials and Methods

Patients and Specimens
Statistical Analysis
All clinical and pathologic data were summarized using descriptive statistics (median and range for continuous variables, frequencies and percentages for categorical variables). Wilcoxon test was used to compare the continuous values among different groups and Fisher exact test was used for the categorical variables. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc, Cary, NC). For all results, P <.05 was considered significant.
Results
Patient and Tumor Characteristics
Seventy-four cases of invasive MBC were identified from two institutions. The median age of the cohort was Two representative MBC cases are illustrated in ❚Image 1❚ (ER+/HER2-) and ❚Image 2❚ (ER+/HER2+).
HR-Positive MBCs
Among 63 HR-positive MBCs, 62 were ductal type and one was lobular type. Lymph node was positive in 24 of 50 MBCs (48%). PR was positive in 56 HR-positive MBCs (88.9%). Nine HR-positive MBCs showed distal metastasis ❚Table 2❚.
The median follow-up time was 34.3 months (range 0.9-198.7 months) and nine HR-positive MBCs (14.3%) developed distal metastasis (six in bone, one in lung, one in liver, and one in both liver and lung) ❚Table 3❚. All nine cases were ductal type with high NG (NG 3). All five ❚Image 1❚ A representative hormone receptor-positive invasive ductal carcinoma of male breast. A, H&E (×200). B, Positive estrogen receptor staining (×200). C, Positive progesterone receptor staining (×200). D, Negative human epidermal growth factor receptor 2 staining (×200).
cases with lymph node status available showed metastasis in lymph nodes. Furthermore, all nine cases showed Magee equation RS more than 18 ( Table 3 ). tumor size, higher NG, and lower ER and PR positivity. Additionally, no significant difference was identified between these groups regarding hormonal therapy or chemotherapy.
The Association Between Magee Equation RS and Distal Metastasis
Discussion
Although MBC is uncommon compared to FBC, more than 2,000 new cases are diagnosed each year in the United States, with an increasing incidence over the past four decades, and approximately 460 men are projected to die from this disease in 2017. 1, 25, 26 It is important to understand the clinical and pathologic features of MBC.
In this retrospective study, we have investigated the clinicopathologic characteristics in 74 MBCs, including 63 HR-positive MBCs, and for the first time, applied Magee equation to predict prognosis in MBCs. Previous studies showed that invasive ductal carcinoma is the main histologic type and constitutes approximately 84.8% to 90% of MBCs, papillary carcinoma is comparatively more common, and lobular carcinoma is rare in men. 1, 3, 5, 9, 10, 27 Our cohort showed a similar distribution of histologic type, with invasive ductal carcinoma as the predominant type. In our study, the majority of MBCs were classified as NG 2, followed by NG 3, which is similar to the grade distribution in FBC. 3, 10, 27 The patient characteristics and tumor features of our study are consistent with previous reported data. 3, 6, 7, 9, 11, 12, 27 In published studies, ER positivity was reported to be 75% to 99.3% vs 57% to 78%, while PR was 58.8% to 96% vs 56% to 66.7% in MBCs and FBCs, respectively. [1] [2] [3] 5, 6, 9, 11, 12, [27] [28] [29] [30] In our cohort, all MBCs except one were ER positive (98.6%), and PR was positive in 86.5%, confirming the high percentage of HR positivity in MBCs. HER2 was positive in 13.5% of our cohort, which is within the reported range (1.7%-42%) and is consistent with previous finding that MBCs have a slightly lower HER2 positivity compared to FBCs. 3, 5, 9, 11, 27, [29] [30] [31] Surprisingly, all HER2-positive MBCs in our cohort were ER positive.
The Magee equation(s) is derived by a linear regression analysis using several pathologic variables and semiquantitative immunohistochemical results. 16, 17 Previous studies demonstrated that the Magee equation(s) effectively predict prognosis in FBC. 16, 17, 23, 24 In our study, Magee equation RS categorized 63 HR-positive cases into three groups based on their RSs (25 with The limitations of our study include its retrospective characteristics with a relatively small cohort and lack of long-term follow-up results. Although univariate analysis demonstrated that increased Magee equation RS was associated with distal metastatic risk in our cohort, multivariate analysis could not be performed due to the low number of cases with metastasis (nine cases). Therefore, a study with a larger cohort is warranted in order to evaluate Magee equation's predictive value in MBCs. MBC is a rare disease with many similarities to FBC. Although the standard treatment extrapolated from FBC may not be completely applicable to MBC, some predictive markers/tests developed for use in FBCs may be utilized to predict recurrence risk and necessity for adjuvant systemic treatment in MBC patients. Our study suggests Magee equation may be one such tool to predict recurrence risk in MBC patients and guide the clinical decisions regarding management.
